3α-Aminocholestane
CAS No. 2206-20-4
3α-Aminocholestane( —— )
Catalog No. M33248 CAS No. 2206-20-4
3α-Aminocholestane (5α-Cholestan-3α-amine) is a potent inhibitor of inositol-5'-phosphatase 1 (SHIP1) containing the SH2 structural domain (IC50 : 2.5 μM) for research and immune-related diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 74 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name3α-Aminocholestane
-
NoteResearch use only, not for human use.
-
Brief Description3α-Aminocholestane (5α-Cholestan-3α-amine) is a potent inhibitor of inositol-5'-phosphatase 1 (SHIP1) containing the SH2 structural domain (IC50 : 2.5 μM) for research and immune-related diseases.
-
Description3α-Aminocholestane is a selective SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) inhibitor with an IC50 of ~2.5 μM.
-
In VitroOPM2 cell viability is effectively reduced by 3α-Aminocholestane (3AC) treatment. RPMI8226 and U266 cells show significantly less sensitivity to 3α-Aminocholestane treatment when compare with OPM2 cells, although viability is decreased significantly at concentrations of ≥12.5 μM. Treatment with 3α-Aminocholestane for 36 h severely reduces the percentage of cells in the S phase, which is accompanied by an increase of cells in the G2/M phase. In contrast, in the less proliferative RPMI8226 and U266 cells, cell cycle progression is blocked in the G0/G1 phase upon 3α-Aminocholestane treatment, in conjunction with a reduced percentage of cells undergoing the S phase.
-
In VivoIt is found that 3α-Aminocholestane (3AC) results in reduced multiple myeloma (MM) growth in vivo, as determined by quantitation of free human Igλ light chain in the plasma after OPM2 challenge. In addition, reduced numbers of circulating OPM2 cells, as determined by human HLA-ABC staining, is observed in peripheral blood from 3α-Aminocholestane-treated mice compare with vehicle controls. Most importantly, 3α-Aminocholestane treatment results in significantly enhanced survival of mice after tumor challenge. In 3α-Aminocholestane-treated mice that resist treatment, it is found that MM tumors exhibit an upregulation of SHIP2, reminiscent of in vitro treatment of OPM2 cells and suggesting that SHIP1 inhibition may select for tumor cells with increased SHIP2 expression.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPhosphatase
-
RecptorPhosphatase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2206-20-4
-
Formula Weight387.68
-
Molecular FormulaC27H49N
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?Ethanol : 50 mg/mL (128.97 mM; Ultrasonic) DMSO : < 1 mg/mL (insoluble or slightly soluble)
-
SMILES[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](N)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chen Z, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21;521(7552):357-61.
molnova catalog
related products
-
Ergosterol
Ergosterol is a steroid extracted from Ganoderma lucidum cystocarp.
-
LFHP-1c
LFHP-1c is a novel PGAM5 inhibitor that shows neuroprotective activity in an ischemic stroke model, preventing BBB destruction after transient middle cerebral artery occlusion (tMCAO) in rats.LFHP-1c can be used to study cerebral ischemic stroke.
-
PTP1B-IN-22
PTP1B-IN-22 is a protein tyrosine phosphatase 1B (PTP1B) inhibitor that inhibits glucose uptake in skeletal muscle L6 myotubes.
Cart
sales@molnova.com